Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L32 pseudogene 17 (RPL32P17) is a non-coding DNA sequence present in the human genome that resembles the ribosomal protein L32 (RPL32) gene but does not encode a functional protein. Pseudogenes like RPL32P17 arise from gene duplication or retrotransposition events and typically accumulate mutations that prevent their translation. They are generally not transcribed or translated under normal cellular conditions, and they are not part of the functional ribosome machinery. While some pseudogenes have been observed to participate in regulatory mechanisms as non-coding RNAs, there are no specific reports of RPL32P17 having such roles. RPL32P17 is not considered a druggable target and lacks therapeutic relevance[1][3][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L32 pseudogene 17 (RPL32P17).